Figure 6.
Summary of NRX-0492 testing in CLL PDX model. Experimental design as in Figure 5. PBMCs from 4 different patients (represented by unique symbols) were inoculated into NSG mice that were divided to vehicle control (Veh) and NRX-0492 (NRX) treatment groups. Each symbol represents 1 mouse. (A) Mean (± SEM) MFI of AF647-BTK in CLL cells in peripheral blood of mice after 7 days of NRX-0492 treatment. (B) Mean (± SEM) MFI of AF647-BTK in CLL cells from spleens on day 22. (C) Mean (± SEM) percentage of CLL cells expressing Ki67 in peripheral blood before treatment start (Day 1) and after 1 week of treatment and in cells from spleens on day 22. (D) Mean (± SEM) percentage of live CLL cells among CD45+ cells in the spleens on day 22. Statistical analysis by unpaired student t test; ns, not significant.

Summary of NRX-0492 testing in CLL PDX model. Experimental design as in Figure 5. PBMCs from 4 different patients (represented by unique symbols) were inoculated into NSG mice that were divided to vehicle control (Veh) and NRX-0492 (NRX) treatment groups. Each symbol represents 1 mouse. (A) Mean (± SEM) MFI of AF647-BTK in CLL cells in peripheral blood of mice after 7 days of NRX-0492 treatment. (B) Mean (± SEM) MFI of AF647-BTK in CLL cells from spleens on day 22. (C) Mean (± SEM) percentage of CLL cells expressing Ki67 in peripheral blood before treatment start (Day 1) and after 1 week of treatment and in cells from spleens on day 22. (D) Mean (± SEM) percentage of live CLL cells among CD45+ cells in the spleens on day 22. Statistical analysis by unpaired student t test; ns, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal